Fiera Capital Corp Sells 867 Shares of Acceleron Pharma Inc (NASDAQ:XLRN)

Fiera Capital Corp reduced its holdings in shares of Acceleron Pharma Inc (NASDAQ:XLRN) by 3.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 26,842 shares of the biopharmaceutical company’s stock after selling 867 shares during the quarter. Fiera Capital Corp owned 0.05% of Acceleron Pharma worth $2,413,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in XLRN. Chevy Chase Trust Holdings Inc. bought a new stake in shares of Acceleron Pharma during the 4th quarter worth $36,000. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Acceleron Pharma by 33.9% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,063 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 269 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Acceleron Pharma by 554.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,237 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 1,048 shares during the last quarter. Sowell Financial Services LLC lifted its position in shares of Acceleron Pharma by 493.4% during the 4th quarter. Sowell Financial Services LLC now owns 1,359 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 1,130 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of Acceleron Pharma during the 4th quarter worth $74,000. Institutional investors and hedge funds own 86.17% of the company’s stock.

In related news, SVP Adam M. Veness sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $85.58, for a total transaction of $513,480.00. Following the completion of the sale, the senior vice president now owns 27,161 shares of the company’s stock, valued at $2,324,438.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin F. Mclaughlin sold 36,774 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $85.51, for a total value of $3,144,544.74. Following the sale, the chief financial officer now directly owns 15,216 shares of the company’s stock, valued at approximately $1,301,120.16. The disclosure for this sale can be found here. 2.50% of the stock is owned by company insiders.

XLRN has been the subject of several research reports. SVB Leerink increased their target price on Acceleron Pharma from $104.00 to $127.00 in a research report on Tuesday, May 12th. Piper Sandler reiterated a “buy” rating and issued a $135.00 target price on shares of Acceleron Pharma in a research report on Monday, April 6th. Barclays reiterated a “buy” rating and issued a $116.00 target price on shares of Acceleron Pharma in a research report on Tuesday, May 12th. BidaskClub downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $137.00 target price on shares of Acceleron Pharma in a research report on Monday, May 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $111.85.

Shares of XLRN opened at $98.59 on Friday. Acceleron Pharma Inc has a 1 year low of $37.01 and a 1 year high of $108.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 15.15 and a current ratio of 15.15. The business has a 50-day moving average of $94.80 and a 200-day moving average of $72.77.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.09). Acceleron Pharma had a negative return on equity of 30.14% and a negative net margin of 182.31%. The company had revenue of $4.30 million for the quarter, compared to the consensus estimate of $5.26 million. During the same quarter last year, the business earned ($0.74) earnings per share. Acceleron Pharma’s revenue was up 53.6% compared to the same quarter last year. Sell-side analysts predict that Acceleron Pharma Inc will post -3.16 EPS for the current fiscal year.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

See Also: What is a trade deficit?

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.